

EBMT SURVEY ON TRANSPLANT AND CELLULAR THERAPY ACTIVITY 2024

Submissions are now given on the online form. You will have received a link to the form from EBMT. This sheet is only to help you count the numbers.

Table 1: Report the number of **patients** receiving their 1st allogeneic and/or 1st autologous transplant in 2024 in rows 1-38. Report non 1st HSCT in row 40. Report the number of **patients** receiving their 1st CAR-T allogeneic and autologous in 2024 in rows 1-38. Report the number of **patients** receiving their 1st Gene therapy in 2024 in rows 1-38. Light grey cells will be automatically calculated by the online form.

Table 2: Report the number of **patients** receiving non HSCT cellular therapies in 2024 by indication and cell type in rows 1-9.

Table 3: Report the number of **patients** receiving their 1st unmanipulated DLI (donor lymphocyte infusion) in 2024 in row 1.

Table 4: Report the number of **patients** receiving Immunosuppressive Treatments (IST) for acquired Bone Marrow Failure Syndromes in 2024 in row 1.

Table 1:		HLA-id sibling			Twin		Haplo and other HLA mismatched related donors			Unrelated			Autologous			Total Allo	Total Auto	Total HSCT	CAR-T		Gene therapy
		BM	PBSC	Cord	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord				Allo	Auto	
1	AML 1st CR																				
2	AML in CR: > 1st CR																				
3	AML not in CR																				
4	AML: therapy related																				
5	AML: MDS related changes																				
6	ALL 1st CR																				
7	ALL non 1st CR																				
8	CML 1st cP																				
9	CML non 1st cP																				
10	MDS																				
11	MDS/MPN																				
12	MPN																				
13	CLL incl. PLL																				
14	PCD - MM																				
15	PCD - other																				
16	Hodgkin Lymphoma																				
17	DLBCL NHL - all types																				
18	Mantle cell lymphoma																				
19	Follicular lymphoma																				
20	Primary mediastinal large B-cell lymphoma (PMBCL)																				
21	Other B-cell NHL																				
22	T-cell NHL																				
23	Solid Tumors - Neuroblastoma																				
24	Solid Tumors - Soft tissue																				
25	Solid Tumors - Ewing sarcoma																				
26	Solid Tumors - Germ cell tumor																				
27	Other solid tumors																				
28	BM aplasia - SAA																				
29	BM aplasia - other																				
30	Thalassemia																				
31	Sickle cell disease																				
32	Inborn Errors of Immunity																				
33	Inborn Errors of Metabolism																				
34	Autoimmune Diseases - MS																				
35	Autoimmune Diseases - SSC																				
36	Autoimmune Diseases - SLE																				
37	Autoimmune Diseases - other																				
38	Others (incl. Histiocytosis)																				
39	Total 1st HSCT/CAR-T/Gene Therapy (row 1-38)																				
40	Additional non 1st HSCT/CAR-T/Gene Therapy																				
41	Total all HSCT/CAR-T/Gene Therapy																				
42	No. patients aged <18 reported in row 1-38																				

	Table 2: Number of patients with non HSCT cellular therapies using manipulated or selected cells (excluding DLI & CAR-T) in 2024	Selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)	
		Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto
1	GvHD																		
2	Graft enhancement/failure																		
3	Autoimmune disease																		
4	Genetic disease																		
5	Infection																		
6	Malignancy - ALL																		
7	Malignancy - Lymphoma																		
8	Malignancy - Myeloma																		
9	Any other indication																		

1	Table 3: Total Number patients with unmanipulated DLI infusions in 2024:		For graft enhancement/failure:		For residual disease:		For relapse:		Per protocol:	
---	--	--	--------------------------------	--	-----------------------	--	--------------	--	---------------	--

1	Table 4: Total Number of patients receiving Immunosuppressive Treatments (IST) for Acquired Bone Marrow Failure Syndromes in 2024:		For Aplastic Anemia (AA):		For other Bone Marrow Failure Syndromes:	
---	--	--	---------------------------	--	--	--